Executive leadership changes designed to grow the company’s expertise, deepen its knowledge base, and drive sales growth.

KNOXVILLE, Tenn. (PRWEB)
October 08, 2019

ChoiceSpine LLC, a privately-held spinal device manufacturer based in Knoxville, TN, today announced several executive leadership changes designed to grow the company’s expertise, deepen its knowledge base, and drive sales growth.

The following changes and new additions have been made in the sales and marketing teams.

• KC Gilbert promoted to Senior Vice President of Strategic Partnerships;
• Keith Clements hired as Vice President of Sales; and
• Ron Moore hired as Senior Director of Marketing.

KC Gilbert ’s promotion to Senior Vice President of Strategic Partnerships expands his current marketing and surgeon education responsibilities to include: Sales Support and Asset Management, Employee Education and Training, Surgeon Relationship Management, Key Account Management, and Healthcare Institution and Distributor Contracting.

“ChoiceSpine is very fortunate to have a leader with KC’s expertise and proven track-record, which makes him an exceptional choice for this new leadership role. KC has demonstrated his strategic-thinking, management style, and surgeon relationships to be key drivers for the company’s future growth plans,” exclaimed Rick Henson and Marty Altshuler, co-founders of ChoiceSpine.

With 13 years of spinal device sales success, Keith Clements recently joined the ChoiceSpine sales team as Vice President of Sales. “We have known Keith, and respectively competed against him, for most of his previous spine sales career. Keith’s salesmanship, work ethic, and spine industry knowledge are a great fit with our corporate culture and business goals,” said Rick and Marty.

“We are excited to see what Ron Moore can do as ChoiceSpine’s Sr. Director of Marketing. His collaborative work style, creative thinking, and industry experience will energize our marketing team to continue to position the company and its product portfolios as industry leaders in the spinal surgery market,” concluded Rick and Marty.

These leadership changes and additions are aligned with the company’s long-term strategic goals and expectations of increased sales growth.

About ChoiceSpine

ChoiceSpine LLC is a spinal device company located in Knoxville, TN and is privately-held by Altus Capital Partners. The Company prides itself on providing excellent products and exceptional service to meet the needs of their customers. ChoiceSpine offers a breadth of innovative and surgeon-focused systems that are designed to be safe, efficient, and easy-to-use. By working closely with physicians and maintaining a service-focused distribution, ChoiceSpine will continue to bring technically-superior spinal products to market.

About Altus Capital Partners

Altus Capital Partners is a private equity firm that makes control investments in middle market manufacturing businesses. We believe that our exclusive focus on manufacturing provides us with a unique understanding of the opportunities and challenges faced by companies in the sector. We utilize a patient, thoughtful investment approach and seek to partner with the management teams of our operating companies to achieve growth. With offices in Wilton, CT and Lincolnshire, IL, Altus Capital Partners has completed 18 platform investments and numerous add on acquisitions since 2003. For more information, please visit http://www.altuscapitalpartners.com.

Share article on social media or email:

AUSTIN, Texas (PRWEB)
October 07, 2019

The documentary Skin Deep: The Battle Over Morgellons has teamed with world-renowned educational distributor Video Project to release the 90 minute film for educational and community screenings. Skin Deep is an investigation by Emmy-winning filmmaker Pi Ware into the fierce controversy surrounding the illness known as Morgellons disease. The documentary is now available for purchase to universities, libraries, medical schools and community groups and comes with a free 20 page study guide.

If you began producing tiny fibers from your body, you would go seek treatment from a doctor, wouldn’t you? Well countless have already experienced this phenomenon, and have found their pleas to physicians fall on deaf ears. Skin Deep is a comprehensive look at Morgellons disease, most well known for afflicting Joni Mitchell. Long thought to be a delusion, new studies and recent discoveries are giving the disease a scientific legitimacy and offering hope to those afflicted. Skin Deep speaks with advocates, skeptics, and sufferers alike to explore this troubling phenomenon, and shines a light on how the medical community reacts to emerging diseases.

Says director Pi Ware, “With many new diseases, there is a period of time before the science of the disease is widely accepted, a time when doctors say, ‘What you’re suggesting goes against what I learned in medical school,’ a time when patients are vulnerable to the prejudice and arrogance of otherwise well-meaning physicians.” Medical history is filled with similar examples: from ulcers (once believed to be caused by stress, now proven to be caused by bacteria) to Multiple Sclerosis (called “hysterical paralysis” until CAT scans and MRIs were invented) to lupus (over 50% of all lupus patients have been told their symptoms are “all in their head”). Ware continues, “There exists a period of time when the victims of a disease are “blamed” for their disease, and the resulting shame, confusion and anger doubles their suffering. Morgellons patients are living in that time right now.”

Skin Deep began filming in the spring of 2015. The film follows several Morgellons patients and physicians who treat them—using antibiotics or anti-psychotics depending on the doctor’s belief system. The film focuses on the battle between a nurse (Cindy Casey-Holman) who is convinced she has a biologically-based disease and a skeptical dermatologist (Dr. Steven Feldman) who favors psychiatric diagnoses. The film climaxes in a showdown at the Morgellons Conference in Austin, Texas, where bridges between doctors and patients will either be built… or burned.

Educational copies of Skin Deep: The Battle Over Morgellons are available at videoproject.com – https://www.videoproject.com/Skin-Deep.html Each purchase includes a free 20 page study guide.

The documentary Skin Deep: The Battle Over Morgellons will also celebrate it’s World Premiere this Saturday, October 5th at 2pm in downtown Los Angeles. Tickets are available at awarenessfestival.org

View the trailer for the film at morgellonsmovie.org.

SKIN DEEP: THE BATTLE OVER MORGELLONS; writer/director, Pi Ware; produced by Lev Mergian, Laura Stoddard, Gary Leva, Patrick Belton, Pi Ware; directors of photography, Sam Price-Waldman, Alex Naufel, Jacob Pinger, PJ Raval; music, Andrew Gross; executive producers, Denise and Jerry James; co- producers, Shelby Hadden, Sydney Niemerow; editors, Tom Putnam, Pi Ware.

Contact: morgellonsdoc@icloud.com

What: Skin Deep: The Battle Over Morgellons Educational & Community distribution When: Now

Where: https://www.videoproject.com/Skin-Deep.html

About the Charles E. Holman Morgellons Disease Foundation:

The Charles E. Holman Morgellons Disease Foundation, based in Austin, TX, is a 501(c) (3) nonprofit organization committed to advocacy and philanthropy in the battle against Morgellons disease. Director, Cindy Casey-Holman, RN, leads the foundation, named for her husband, Charles E. Holman, a pioneer in the fight against Morgellons disease. Currently, there is no public funding and very limited private funding to support research for this disease, and the CEHMDF is the recognized authority and primary funding source for Morgellons disease medical/scientific research. Donations are tax-deductible​ in the US. To learn more about Morgellons disease go to: http://www.MorgellonsDisease.org

Contact information:

https://thecehf.org

Share article on social media or email:

At Visikol we have assisted many pharma and biotech companies with making sense of large multi-dimensional data sets and extracting key quantitative metrics

WHITEHOUSE STATION, N.J. (PRWEB)
October 07, 2019

Imaging data sets are generated through drug discovery research projects using a wide-range of imaging modalities such as optical projection tomography, optical coherence tomography, echocardiogram, light sheet microscopy, MRI and X-ray CT. While many research groups have the capability to generate these data sets inhouse, a lot of research groups struggle with transforming these large and sometimes noisy data sets into actionable insights that allow them to make more informed decisions during the drug discovery process.

“At Visikol, we have assisted many pharma and biotech companies with making sense of large multi-dimensional data sets and extracting key quantitative metrics. We find that most off-the-shelf image analysis platforms are limited in their flexibility and a lot of research groups reach out to us when they need help with building customized image analysis solutions,” described Visikol Chief Science Officer Dr. Tom Villani.

To start an image analysis project with Visikol, Clients discuss with the Visikol project team the types of end-points they are interested in and the details of their specific research question. Clients will then send along a hard drive of data or upload files to Visikol’s secure cloud-based file sharing platform. From this data, Visikol can apply its 3Screen™ image analysis tools which are a suite of digital pathology algorithms designed for use with both two-dimensional and three-dimensional image data sets. These tools are ultimately used to transform the data sets provided by Clients into actionable insights that allow Clients to make more informed decisions during the drug discovery processes.

“Over the last few years, we have worked with Clients on projects ranging from analyzing 40-plex multiplex slide data sets and processing thousands of in vivo optical coherence retina imaging data sets to identifying novel image-based biomarkers such as in our recent work with Enzyvant Therapeutics,” described Visikol Director of Imaging Services Dr. Graeme Gardner. While there are many digital pathology companies in the marketplace today offering services as well as off-the-shelf digital pathology solutions, Visikol has become a leader in this space through its expertise with multi-dimensional datasets, on-demand custom software development and image analysis software validation and clinical deployment.

About Visikol

Visikol is a CRO focused on advanced drug discovery that is leading the fields of bio-imaging, bioinformatics and image analysis. We conduct end-to-end drug discovery services that include both 2D and 3D in vitro models and assays, 3D whole mount tissue imaging, digital pathology and custom drug discovery projects. Visikol offers a portfolio of drug discovery services ranging from 2D and 3D cell culture model and assay development to in vitro screening, animal tissue histology and automated image processing. The focus of these services is to transform tissues into images and ultimately into quantitative data sets that can be mined for actionable insights that help our Clients make more informed decisions during the drug discovery process. Additionally, Visikol manufactures and sells a suite of tissue clearing reagents and 3D immuno-labeling kits. These products allow researchers to easily and rapidly image whole tissues and 3D cell culture models in 3D instead of traditional 2D sectioning. For more information about Visikol or its services, please visit our website at visikol.com.

Share article on social media or email:

“We are humbled and honored to have been awarded Innovative Technology contracts for these three products. This award from Vizient validates the level of clinical excellence LINET brings to the market,” said Colin Bain, President and CEO of LINET Americas.

CHARLOTTE, N.C. (PRWEB)
October 07, 2019

LINET announced its Multicare ICU bed, AVE 2 Labor & Delivery bed and Eleganza 5 Med Surg bed have received Innovative Technology contracts from Vizient, Inc., the largest member-driven health care performance improvement company in the country. The contract was based on a recommendation of these healthcare beds, intended for critical care, acute care, and labor and delivery environments, by hospital experts in these categories who serve on one of Vizient’s member-led councils.

Multicare, LINET’s intensive care bed, uses innovative technologies to create an ideal combination of clinical benefits for patients and staff – medical, nursing and therapy. Unique features support vital patient functions and provide excellent working conditions for staff to help minimize the risks associated with caring for high acuity patients. Innovative features include:

• 
  Programmable Automatic Lateral Therapy to treat pulmonary complications
• Frame-based lateral tilt up to 30 degrees for easy patient repositioning
• Passive leg raise capability to 38 degrees for sepsis protocol
• Motorized patient transport with automatic fifth wheel and variable speeds to assist with movement of patients throughout the hospital
• Automatic i-Brake system engages after 60 seconds to lock castors to help prevent patient falls
• Ergoframe’s auto-contour position helps reduce patient migration to foot of bed and reduces pressure and shear on patient’s skin
• Hands-free foot controls and one touch hand controls for easy product operation

AVE 2, LINET’s labor and delivery bed, has many features that make the birthing process easier for both the mother and the medical staff. Thanks to its broad range of accessories and positions, the patient has the ability to choose a delivery method that best suits her birthing plan. Innovative features include:

• Integrated retractable foot section for quick bed reconfiguration during labor
• Easy adjustments for siderail/headrail and leg sections
• Tilting U-shape seat for better patient access
• Independent motorized seat tilt for more position options
• Multiple articulation positions available to best suit the mother

Eleganza 5, LINET’s acuity-adaptable bed, helps make routine nursing activities safer, easier and faster for enhanced nursing efficiency and better patient outcomes. Advanced features reduce the amount of stress and strain on caregivers while providing additional safety and comfort for patients. Innovative features include:

• Frame-based lateral tilt up to 15 degrees for easier patient positioning and transfers
• Ergoframe’s auto-contour position to reduce patient migration to foot of bed and reduce pressure and shear on patient’s skin
• Built-in patient sit-to-stand assist for easier ingress/egress to assist with early patient ambulation

“We are humbled and honored to have been awarded Innovative Technology contracts for these three products. This award from Vizient validates the level of clinical excellence LINET brings to the market,” said Colin Bain, President and CEO of LINET Americas.

“Hospitals and providers are looking for innovations that offer unique and cumulative benefit over other products available on the market today. Our member council determined these technologies met the criteria to be awarded with the Innovative Technology contract. Congratulations to LINET on receiving this status,” said Debbie Archer, director of procurement and Vizient Innovative Technology Program leader.

Vizient represents a diverse membership base that includes academic medical centers, pediatric facilities, community hospitals, integrated health delivery networks and non-acute health care providers and represents approximately $100 billion in annual purchasing volume. Through its Innovative Technology Program, Vizient works with member-led councils and task forces to review potentially innovative products. If it is determined that a product is innovative, Vizient may award a contract outside of the competitive bid cycle.

LINET Founded in 1990, LINET is an international leader in healthcare technology with patient beds installed in over 100 countries. Considered one of the most dynamic companies in the healthcare field, LINET offers a new and unique approach to the hospital bed market. LINET manufacturers innovative beds for the ICU and Medical-Surgical, Labor & Delivery, One-Day Care, and Long-Term Care environments that promote patient and nurse safety, facilitate early mobilization, assist in better adherence to turning schedules, improve pain management and help reduce infection rates. The company’s U.S. headquarters is based in Charlotte, NC. Please visit http://www.linetamericas.com for more information.

Share article on social media or email:

“Everyone on the Forcura team is responsible for helping us grow as a company and I’m proud of each of their contributions to our shared mission of empowering better patient care,” said Founder and CEO Craig Mandeville.

JACKSONVILLE, Fla. (PRWEB)
October 03, 2019

Forcura has been ranked as No. 23 among healthcare suppliers/vendors in Modern Healthcare’s 2019 Best Places to Work in Healthcare list. The complete list of this year’s winner rankings is available here. Modern Healthcare will publish a special supplement featuring ranked lists of all the winners along with the September 30 issue.

“This recognition by Modern Healthcare is a great accomplishment towards our goals to become the best healthcare technology company,” said Founder and CEO Craig Mandeville. “Everyone on the Forcura team is responsible for helping us grow as a company and I’m proud of each of their contributions to our shared mission of empowering better patient care.”

Modern Healthcare and its Best Places to Work in Healthcare award winners have accomplished much over the years, empowering healthcare organizations, and the people who work for them, to realize their full potential. Modern Healthcare partners with the Best Companies Group on the assessment process, which includes an extensive employee survey.

Forcura has recently been named to the Inc. 5000 Fastest Growing Companies List, received awards for Best Place to Work, and Best UI/UX Design in SaaS.

“With record unemployment levels, organizations face stiff competition to attract and retain top talent. The providers and companies making this year’s Best Places to Work in Healthcare list understand the importance of creating an environment where employees can not only excel in their own development but contribute to the mission of improving care delivery,” said Aurora Aguilar, editor of Modern Healthcare. “An appreciation—and dedication—to their organization’s mission was one of the most common refrains from employees filling out surveys this year.”

Forcura was honored at the 2019 Best Places to Work Awards Dinner on Thursday, September 26, at the Renaissance Dallas Hotel. This is the 2nd year Forcura has made the list.

About Modern Healthcare

Modern Healthcare is the most trusted business news and information brand in the healthcare industry. Combining the power of a print publication, 24-7 digital news products, robust research and event platforms, Modern Healthcare empowers healthcare leaders and influencers to make timely and informed business decisions. To learn more or subscribe, go to https://www.modernhealthcare.com/subscribe.

About Forcura

Forcura, a leading healthcare technology company headquartered in Jacksonville, Florida, facilitates continuity of care via technology, analytics and a deep commitment to enabling better patient care. The Forcura suite of tools is powered by Forcura Connect, a proprietary framework for standardizing interoperability and integration among post-acute health care organizations, physicians, electronic health records (EHRs) and other supporting technology vendors. Through our technology and analytics solutions, we are a step closer every day to elevating the opportunities of post-acute care. The company has received awards for Fastest Growing Company for the fourth consecutive year, Best UI/UX Design in SaaS, and Best Places to Work by Inc. Magazine. For more information visit http://www.forcura.com, call 800-378-0596 or follow Forcura on LinkedIn.

Share article on social media or email: